Donald Yapman Leung
Physician at Geneva St, Englewood, CO
License number
Colorado 29944
Issued Date
Jan 11, 1990
Renew Date
May 1, 2015
Expiration Date
Apr 30, 2017
Type
Physician
Address
Address
5267 S Geneva St, Englewood, CO 80111
Personal information
See more information about Donald Yapman Leung at radaris.comName
Address
Phone
400 S Steele St UNIT 22, Denver, CO 80209
Denver, CO
5267 Geneva St, Englewood, CO 80111
8623 Colonial Dr, Littleton, CO 80124
Professional information
See more information about Donald Yapman Leung at trustoria.com
Method For Treating Kawasaki Syndrome By Administration Of An Anti-Tsst-1 Agent Which Is Not Gamma Globulin
Method For Treating Kawasaki Syndrome By Administration Of An Anti-Tsst-1 Agent Which Is Not Gamma Globulin
US Patent:
5460813, Oct 24, 1995
Filed:
Apr 5, 1993
Appl. No.:
8/042863
Inventors:
Donald Leung - Englewood CO
Patrick Schlievert - Minneapolis MN
Cody Meissner - Arlington MA
David Fulton - Chestnut Hill MA
Brian Kotzin - Denver CO
Patrick Schlievert - Minneapolis MN
Cody Meissner - Arlington MA
David Fulton - Chestnut Hill MA
Brian Kotzin - Denver CO
Assignee:
National Jewish Center for Immunology and Respiratory Medicine - Denver CO
International Classification:
A61K 3940, A61K 3943, A61K 3174, A61K 31545, A61K 31675
US Classification:
424115
Abstract:
The invention relates to various methodologies for diagnosing Kawasaki syndrome. Various bacteria, including TSST-1 producing Staphylococcus aureus, and SPEB and SPEC producing streptococcus have been found to be indicative of the pathological condition. Also described is a Kawasaki syndrome implicated isolate of S. aureus, and therapeutic methodologies for preventing treating the condition. These involve the administration of anti-TSST-1 agents which are not gamma globulin.
Methods Of Predicting Therpeutic Response In Atopic Dermatitis To Il-31 Antagonists
Methods Of Predicting Therpeutic Response In Atopic Dermatitis To Il-31 Antagonists
US Patent:
2006018, Aug 24, 2006
Filed:
Feb 14, 2006
Appl. No.:
11/353454
Inventors:
Donald Leung - Englewood CO, US
Janine Bilsborough - Seattle WA, US
Jane Gross - Seattle WA, US
Janine Bilsborough - Seattle WA, US
Jane Gross - Seattle WA, US
International Classification:
A61K 39/395
US Classification:
424143100
Abstract:
The present invention relates to predicting therapeutic response of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cells in atopic dermatitis. The invention also includes methods of predicting a therapeutically responsive patient population.
Cationic Steroid Antimicrobial Compositions And Methods Of Use
Cationic Steroid Antimicrobial Compositions And Methods Of Use
US Patent:
7754705, Jul 13, 2010
Filed:
Jan 31, 2007
Appl. No.:
11/669866
Inventors:
Paul B. Savage - Mapleton UT, US
Donald Y Leung - Englewood CO, US
Donald Y Leung - Englewood CO, US
Assignee:
Brigham Young University - Provo UT
National Jewish Medical and Research Center - Denver CO
National Jewish Medical and Research Center - Denver CO
International Classification:
A61K 31/56
US Classification:
514182, 514169
Abstract:
The invention provides methods for decreasing or inhibiting poxvirus infection or pathogenesis of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with poxvirus infection or pathogenesis in vitro, ex vivo or in vivo, or an adverse side effect of poxvirus infection or pathogenesis in vitro, ex vivo or in vivo. In one embodiment, a method of the invention includes treating a subject with an invention compound (e. g. , cationic steroid antimicrobial or CSA).
Isolated Nucleic Acid Molecule Coding For Toxin Associated With Kawasaki Syndrome And Uses Thereof
Isolated Nucleic Acid Molecule Coding For Toxin Associated With Kawasaki Syndrome And Uses Thereof
US Patent:
5476767, Dec 19, 1995
Filed:
Nov 12, 1993
Appl. No.:
8/152456
Inventors:
Donald Leung - Englewood CO
Patrick Schlievert - Minneapolis MN
Cody Meissner - Arlington MA
David Fulton - Chestnut Hill MA
Patrick Schlievert - Minneapolis MN
Cody Meissner - Arlington MA
David Fulton - Chestnut Hill MA
Assignee:
Regents of the University of Minnesota - Minneapolis MN
New England Medical Center Hospital, Inc. - Boston MA
National Jewish Center for Immunology and Respiratory Medicine - Denver CO
New England Medical Center Hospital, Inc. - Boston MA
National Jewish Center for Immunology and Respiratory Medicine - Denver CO
International Classification:
C07H 2102, C07H 2104, C12Q 168, C12N 510
US Classification:
435 6
Abstract:
The invention relates to isolated nucleic acid molecules coding for toxins associated with Kawasaki Syndrome. Also described are various applications of the nucleic acid molecules.
Cationic Steroid Antimicrobial Compositions And Methods Of Use
Cationic Steroid Antimicrobial Compositions And Methods Of Use
US Patent:
8211879, Jul 3, 2012
Filed:
Sep 7, 2010
Appl. No.:
12/876993
Inventors:
Paul B. Savage - Mapleton UT, US
Donald Leung - Englewood CO, US
Donald Leung - Englewood CO, US
Assignee:
Brigham Young University - Provo UT
National Jewish Medical and Research Center - Denver CO
National Jewish Medical and Research Center - Denver CO
International Classification:
A61K 31/56, A61K 31/58
US Classification:
514169, 514172
Abstract:
The invention provides methods for decreasing or inhibiting herpesviridae (HV) infection or pathogenesis of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with a herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo, or an adverse side effect of herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo. In one embodiment, a method of the invention includes treating a subject with an invention compound (e. g. , cationic steroid antimicrobial or CSA).
Methods Of Treating Diseases Which Are Mediated By Cutaneous Lymphocyte Antigen Positive Cells
Methods Of Treating Diseases Which Are Mediated By Cutaneous Lymphocyte Antigen Positive Cells
US Patent:
2006018, Aug 24, 2006
Filed:
Feb 14, 2006
Appl. No.:
11/353427
Inventors:
Donald Leung - Englewood CO, US
Janine Bilsborough - Seattle WA, US
Jane Gross - Seattle WA, US
Janine Bilsborough - Seattle WA, US
Jane Gross - Seattle WA, US
International Classification:
A61K 39/395
US Classification:
424143100
Abstract:
The present invention relates to methods of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cell. In particular, diseases or disorders including contact dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous T cell lymphoma, bullous pemphigoid, alopecia aereata, vitiligo, acne rosacea, prurigo nodularis, and herpes simplex virus, or combination thereof will benefit from the administration of an IL-31 antagonist. The invention also includes methods of predicting a therapeutically responsive patient population.
Method For Diagnosing Kawasaki Syndrome
Method For Diagnosing Kawasaki Syndrome
US Patent:
5470716, Nov 28, 1995
Filed:
Apr 5, 1993
Appl. No.:
8/042731
Inventors:
Donald Leung - Englewood CO
Patrick Schlievert - Minneapolis MN
Cody Meissner - Arlington MA
David Fulton - Chestnut Hill MA
Patrick Schlievert - Minneapolis MN
Cody Meissner - Arlington MA
David Fulton - Chestnut Hill MA
Assignee:
National Jewish Center For Immunology and Respiratory Medicine - Denver CO
New England Medical Center Hospital, Inc. - Boston MA
University of Minnesota - Minneapolis MN
Regents of the University of Minnesota - Minneapolis MN
New England Medical Center Hospital, Inc. - Boston MA
University of Minnesota - Minneapolis MN
Regents of the University of Minnesota - Minneapolis MN
International Classification:
C12Q 104, C12Q 100, G01N 3348
US Classification:
435 34
Abstract:
The invention relates to various methodologies for diagnosing Kawasaki syndrome. Various bacteria, including TSST-1 producing Staphylococcus aureus, and SPEB and SPEC producing streptococcus have been found to be indicative of the pathological condition. Also described is a Kawasaki syndrome implicated isolate of S. aureus, and therapeutic methodologies for preventing treating the condition.
Isolated Toxin Associated With Kawasaki Syndrome
Isolated Toxin Associated With Kawasaki Syndrome
US Patent:
5585465, Dec 17, 1996
Filed:
May 12, 1995
Appl. No.:
8/440221
Inventors:
Donald Leung - Englewood CO
Patrick Schlievert - Edina MN
Cody Meissner - Arlington MA
Patrick Schlievert - Edina MN
Cody Meissner - Arlington MA
Assignee:
National Jewish Center for Immunology and Respiratory Medicine - Denver CO
New England Medical Center Hospital, Inc. - Boston MA
Regents of the University of Minnesota - Minneapolis MN
New England Medical Center Hospital, Inc. - Boston MA
Regents of the University of Minnesota - Minneapolis MN
International Classification:
C07K 1431
US Classification:
530350
Abstract:
The invention relates to the isolated toxin associated with Kawasaki syndrome and the bacteria from which these are isolated.
Cationic Steroid Antimicrobial Compositions And Methods Of Use
Cationic Steroid Antimicrobial Compositions And Methods Of Use
US Patent:
2007019, Aug 16, 2007
Filed:
Jan 31, 2007
Appl. No.:
11/669803
Inventors:
Paul Savage - Mapleton UT, US
Donald Leung - Englewood CO, US
Donald Leung - Englewood CO, US
International Classification:
C12Q 1/68, C12P 21/06
US Classification:
435006000, 435069100
Abstract:
The invention provides methods for decreasing or inhibiting herpesviridae (HV) infection or pathogenesis of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with a herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo, or an adverse side effect of herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo. In one embodiment, a method of the invention includes treating a subject with an invention compound (e.g., cationic steroid antimicrobial or CSA).
Methods Of Treating Diseases Which Are Mediated By Cutaneous Lymphocyte Antigen Positive Cells
Methods Of Treating Diseases Which Are Mediated By Cutaneous Lymphocyte Antigen Positive Cells
US Patent:
2009028, Nov 12, 2009
Filed:
Jul 2, 2009
Appl. No.:
12/497383
Inventors:
Donald Y.M. Leung - Englewood CO, US
Janine Bilsborough - Seattle WA, US
Jane A. Gross - Seattle WA, US
Janine Bilsborough - Seattle WA, US
Jane A. Gross - Seattle WA, US
International Classification:
A61K 39/395, A61P 17/00, A61P 17/02, A61P 17/10
US Classification:
4241351, 4241391, 4241331
Abstract:
The present invention relates to methods of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cell. In particular, diseases or disorders including contact dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous T cell lymphoma, bullous pemphigoid, alopecia aereata, vitiligo, acne rosacea, prurigo nodularis, and herpes simplex virus, or combination thereof will benefit from the administration of an IL-31 antagonist. The invention also includes methods of predicting a therapeutically responsive patient population.